Literature DB >> 11090080

The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.

J E Parker1, G J Mufti, F Rasool, A Mijovic, S Devereux, A Pagliuca.   

Abstract

Bone marrow CD34(+) cell apoptosis (annexin V), proliferation (Ki-67), and Bcl-2-related protein expression was evaluated by flow cytometry in 102 patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia secondary to MDS (MDS-AML) and in 30 normal donors (NBM). Apoptosis was significantly increased in refractory anemia (RA)/RA with ringed sideroblasts (RARS) (56.9% [20.4%-93.6%]) and refractory anemia with excess blasts (RAEB) (51.2% [25.2%-76. 6%]) compared with NBM (16.7% [3.4%-35.3%], P <.0001). In RA/RARS, apoptosis always exceeded proliferation (Ki-67-positivity, 26.1% [9.5%-47.8%]; apoptosis:proliferation ratio 2.08 [1.15-3.63]); whereas in RAEB, this ratio equalized (1.14 [0.93-2.08]) due to increased proliferation (40.4% [22%-69.5%]). Progression to RAEB in transformation (RAEB-t)/MDS-AML was associated with a significant reduction in apoptosis (22.3% [2.1%-53.2%]; P <.0001) and proliferation (16.8% [1.9%-75.8%); P =.04; ratio 1.69 [0.16-12.21]). Pro-apoptotic (Bax/Bad) versus anti-apoptotic (Bcl-2/Bcl-X) Bcl-2-related protein ratios were increased in RA/RARS compared with NBM (2.57 [1.93-9.42] versus 1.89 [0.65-4.1]; P =.06), whereas disease progression was associated with significantly reduced ratios (1.16 [0.06-3.32]; P <.0001) due primarily to increased Bcl-2 expression. Apoptosis and Bax/Bad:Bcl-2/Bcl-X ratio were inversely correlated with both International Prognostic Scoring System score and cytogenetic risk group; highest levels observed in patients with low score and/or good risk cytogenetics. There was a trend toward an association between Bcl-2-related protein expression and apoptosis (P =.07). This study indicates that MDS progression arises through multiple hits that alter levels of CD34(+) cell apoptosis and proliferation. Early disease is associated with excessive apoptosis and elevated ratio of apoptosis to proliferation. Increased proliferative rates are observed in RAEB, whereas leukemic transformation arises through inhibition of apoptosis rather than excessive cell growth. Although disease progression is accompanied by a fall in pro-apoptotic versus anti-apoptotic Bcl-2-related protein ratios, heterogeneity in patterns of protein expression indicates that factors additional to Bcl-2 family members play a role in the deregulated apoptosis in MDS. (Blood. 2000;96:3932-3938)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  75 in total

1.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

2.  Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Authors:  S Jilg; V Reidel; C Müller-Thomas; J König; J Schauwecker; U Höckendorf; C Huberle; O Gorka; B Schmidt; R Burgkart; J Ruland; H-J Kolb; C Peschel; R A J Oostendorp; K S Götze; P J Jost
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

3.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

4.  Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.

Authors:  Yue Zhang; Xiaomei Yan; Goro Sashida; Xinghui Zhao; Yalan Rao; Susumu Goyama; Susan P Whitman; Nicholas Zorko; Kelsie Bernot; Rajeana M Conway; David Witte; Qian-Fei Wang; Daniel G Tenen; Zhijian Xiao; Guido Marcucci; James C Mulloy; H Leighton Grimes; Michael A Caligiuri; Gang Huang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

Review 5.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 6.  New drugs in acute myeloid leukemia.

Authors:  Francis J Giles
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

7.  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Authors:  Yuqing Sun; Bo Zhou; Fengbiao Mao; Jing Xu; Hongzhi Miao; Zhenhua Zou; Le Tran Phuc Khoa; Younghoon Jang; Sheng Cai; Matthew Witkin; Richard Koche; Kai Ge; Gregory R Dressler; Ross L Levine; Scott A Armstrong; Yali Dou; Jay L Hess
Journal:  Cancer Cell       Date:  2018-09-27       Impact factor: 31.743

8.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

9.  Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts.

Authors:  Mariana O Baratti; Yuri B Moreira; Fabiola Traina; Fernando F Costa; Sergio Verjovski-Almeida; Sara T Olalla-Saad
Journal:  BMC Med Genomics       Date:  2010-07-15       Impact factor: 3.063

10.  PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.

Authors:  A A Guirguis; C I Slape; L M Failla; J Saw; C S Tremblay; D R Powell; F Rossello; A Wei; A Strasser; D J Curtis
Journal:  Cell Death Differ       Date:  2016-01-08       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.